EXPLANATORY STATEMENT
Health Insurance Act 1973
Health Insurance (Section 3C General Medical Services – Botox Injection) Amendment (Addition of Xeomin Injection) Determination 2025
Subsection 3C(1) of the Health Insurance Act 1973 (the Act) provides that the Minister may, by legislative instrument, determine that a health service not specified in an item in the general medical services table (the GMST) shall, in specified circumstances and for specified statutory provisions, be treated as if it were specified in the GMST.
The GMST is set out in the regulations made under subsection 4(1) of the Act. The most recent version of the regulations is the Health Insurance (General Medical Services Table) Regulations 2021.
This instrument relies on subsection 33(3) of the Acts Interpretation Act 1901, which provides that a power to make a legislative or administrative instrument includes the power to repeal, rescind, revoke amend, or vary any that instrument in the same manner and subject to the same conditions.
Purpose
The purpose of the Health Insurance (Section 3C General Medical Services – Botox Injection) Amendment (Addition of Xeomin Injection) Determination 2025 (the Amendment Determination) is to amend the Health Insurance (Section 3C General Medical Services – Botox Injection) Determination 2020 from 1 March 2026.
The Amendment Determination will enable the inclusion of IncobotulinumtoxinA (Xeomin) for the treatment of moderate to severe upper limb spasticity due to cerebral palsy for patients aged two years and older under Medicare Benefits Schedule (MBS) item 18361.
The amendment of MBS item 18361 was agreed to by the Minister for Health and Ageing on 8 October 2025 through the Minister’s authority to approve certain Medical Services Advisory Committee (MSAC) recommendations for new and amended MBS items outside of a budget process.
Consultation
At its meeting of 31 July 2025, MSAC supported the amendment of existing MBS item 18361 to include the injection of Xeomin for the treatment of upper limb spasticity in patients with cerebral palsy aged 2 years and older.
The Cerebral Palsy Alliance, the Rehabilitation Medicine Society of Australia and New Zealand and the Movement Disorder Society of Australia and New Zealand were consulted on the MSAC application and supported the amendment to MBS item 18361.
The Amendment Determination is a legislative instrument for the purposes of the Legislation Act 2003.
The Amendment Determination commences on 1 March 2026.
Details of the Amendment Determination are set out in the Attachment.
Authority: Subsection 3C(1) of the
Health Insurance Act 1973
ATTACHMENT
Details of the Health Insurance (Section 3C General Medical Services – Botox Injection) Amendment (Addition of Xeomin Injection) Determination 2025
Section 1 – Name
Section 1 provides for the instrument to be referred to as the Health Insurance (Section 3C General Medical Services – Botox Injection) Amendment (Addition of Xeomin Injection) Determination 2025 (the Amendment Determination).
Section 2 – Commencement
Section 2 provides for the Amendment Determination to commence on 1 March 2026.
Section 3 – Authority
Section 3 provides that the Amendment Determination is made under subsection 3C(1) of the Health Insurance Act 1973.
Section 4 – Schedules
Section 4 provides that each instrument that is specified in a Schedule to the Amendment Determination is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to the Amendment Determination has effect according to its terms.
Schedule 1 – Amendments
Item 1 repeals the Group T1 table and substitutes a new table to: add Xeomin for the treatment of cerebral palsy to the item descriptor for MBS item 18361; update the table Group from T1 to T11; add column numbers; and update the current MBS fee for the item.
Statement of Compatibility with Human Rights
Prepared in accordance with Part 3 of the Human Rights (Parliamentary Scrutiny) Act 2011
Health Insurance (Section 3C General Medical Services – Botox Injection) Amendment (Addition of Xeomin Injection) Determination 2025
This instrument is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011.
Overview of the Determination
The purpose of the Health Insurance (Section 3C General Medical Services – Botox Injection) Amendment (Addition of Xeomin Injection) Determination 2025 (the Amendment Determination) is to amend the Health Insurance (Section 3C General Medical Services – Botox Injection) Determination 2020 from 1 March 2026.
The Amendment Determination will enable the inclusion of IncobotulinumtoxinA (Xeomin) for the treatment of moderate to severe upper limb spasticity due to cerebral palsy for patients aged 2 years and older under Medicare Benefits Schedule (MBS) item 18361.
The amendment of MBS item 18361 was agreed to by the Minister for Health and Ageing on 8 October 2025 through the Minister’s authority to approve certain Medical Services Advisory Committee (MSAC) recommendations for new and amended MBS items outside of a budget process.
Human rights implications
This instrument engages Articles 2, 3, 9, 12, 16, and 26 of the International Covenant on Economic Social and Cultural Rights (ICESCR), specifically the rights to equality and non-discrimination, health and social security.
The Right to Health
The right to the enjoyment of the highest attainable standard of physical and mental health is contained in Article 12(1) of the ICESCR. The UN Committee on Economic Social and Cultural Rights (the Committee) has stated that the right to health is not a right for each individual to be healthy, but is a right to a system of health protection which provides equality of opportunity for people to enjoy the highest attainable level of health.
The Committee reports that the ‘highest attainable standard of health’ takes into account the country’s available resources. This right may be understood as a right of access to a variety of public health and health care facilities, goods, services, programs, and conditions necessary for the realisation of the highest attainable standard of health.
The Right to Social Security
The right to social security is contained in Article 9 of the ICESCR. It requires that a country must, within its maximum available resources, ensure access to a social security scheme that provides a minimum essential level of benefits to all individuals and families that will enable them to acquire at least essential health care. Countries are obliged to demonstrate that every effort has been made to use all resources that are at their disposal in an effort to satisfy, as a matter of priority, this minimum obligation.
The Committee reports that there is a strong presumption that retrogressive measures taken in relation to the right to social security are prohibited under ICESCR. In this context, a retrogressive measure would be one taken without adequate justification that had the effect of reducing existing levels of social security benefits, or of denying benefits to persons or groups previously entitled to them. However, it is legitimate for a Government to re-direct its limited resources in ways that it considers to be more effective at meeting the general health needs of all society, particularly the needs of the more disadvantaged members of society.
The Right of Equality and Non-Discrimination
The rights of equality and non-discrimination are contained in Articles 2, 16 and 26 of the International Covenant on Civil and Political Rights (ICCPR). Article 26 of the ICCPR requires that all persons are equal before the law, are entitled without any discrimination to the equal protection of the law and in this respect, the law shall prohibit any discrimination and guarantee to all persons equal and effective protection against discrimination on any ground such as race, colour, sex, language, religion, political or other opinion, national or social origin, property, birth or other status.
Analysis
This instrument will reflect contemporary clinical practice to ensure that patients continue to have access to health and social security through relevant subsidised services on the Medicare Benefits Schedule.
Conclusion
This instrument is compatible with human rights as it maintains the right to health and the right to social security and the right of equality and non-discrimination as it will enable an MBS benefit for Xeomin injection services for the treatment of upper and lower limb spasticity in patients with cerebral palsy aged two years and older.
Louise Riley
Assistant Secretary
MBS Policy and Reviews Branch
Medicare Benefits and Digital Health Division
Health Resourcing Group
Department of Health, Disability and Ageing